Rom J Morphol Embryol ; 60 4 : Research over the past decades has been aimed at clarifying the mechanisms of ovarian oncogenesis, to identify ways of transforming normal cells into a neoplastic cell, as well as discovering of tumor markers used in the detection of neoplastic processes, along with the synthesis of therapeutic substances, which would influence its development.
AIMS: In our study, we aimed to determine the serum concentrations of cancer antigen CAhuman epididymis protein 4 HE4 and the risk of ovarian malignancy algorithm ROMA in patients with ovarian tumors, as well as assessing their diagnostic performance.
Furthermore, another objective of the study was to identify a concordant relation between serological and immunohistochemical IHC biomarkers in supporting and aiding the differentiation between benign and malignant tumors, here including the group of borderline tumors.
The patients were divided into two groups: the group of patients with benign tumors, subdivided into pre-menopausal 51 cases, In parallel, we investigated 35 women as control subjects, who did not have a personal history of ovarian tumors. RESULTS: In our study, we have observed that for the analyzed parameters, CA, HE4, and the ROMA index, significantly higher serum concentrations were detected in the malignant tumor group, when these have been compared to the values obtained for the pre-menopausal and for the post-menopausal subgroup, respectively.
The IHC results prostate volume normal ultrasound showed different expression patterns for the different markers studied.
Corroboration of the results of the serological biomarkers with the IHC data is necessary and useful for differentiating borderline tumors and for their final integration as benign or malignant ovarian tumors. This can only be done for the cases with surgical resections, thus having tissue available.
Due to the superior sensitivity and specificity of CA and HE4, we can consider these markers as an alternative or additional diagnostic criterion to the ROMA index.